Braveheart BioBRVE
Recorded

Braveheart Bio Investor update

Review the key takeaways and the transcript of this earnings call.

Period 0Duration58 minParticipants10

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Welcome to the Braveheart Bio call today. My name is Josh, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference call is being recorded. I will now turn the call over to Paul Rickey, Chief Financial Officer at Braveheart. Paul, you may begin. Thank you, Josh.

Paul RickeyCFO

Good afternoon, and thank you all for joining us. Before we begin, I'd like to remind you that today's remarks contain forward-looking statements. Please refer to the risk factors in our most recent filings with the SEC for a discussion of the factors that could cause actual results to differ materially from what we will cover in today's discussion. Earlier this afternoon, we, along with our partner, Hengrui, presented data from our BHB-1893 program at the American Heart Association Scientific Sessions 2026. A press release describing these results, as well as the presentations themselves, are available on our website at braveheart.bio. With us today, we are pleased to have Dr. Anjali Owens, Associate Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania. Dr. Owens is also Medical Director of Penn Center for Inherited Cardiovascular Disease.

Paul RickeyCFO

Also joining us is Dr. Mariko Harper of Virginia Mason Franciscan Health, where she is the Medical Director of Hypertrophic Cardiomyopathy Center of Excellence. To begin, we'll have Dr. Travis Murdoch, our Chief Executive Officer and Board Director, share an update.

Travis MurdochCEO and Board Director

Thank you, everyone, for spending time with us today. We are a late-stage clinical biotechnology company focused on developing BHB-1893 to improve the lives of patients with HCM and related conditions. We believe that our therapeutic candidate, BHB-1893, has differentiated potential in HCM across efficacy, safety, and ease of use. We plan on sharing with you today further data that reinforces this profile, while also guides our development plan to further develop a preferred treatment option for patients. We are advancing global phase III development in both forms of HCM. In obstructive HCM, we have initiated LIONHEART-HCM, which aims to demonstrate the efficacy and safety of BHB-1893 head-to-head with beta blockers, with an option for single titration at week four.

Travis MurdochCEO and Board Director

In addition, we have a fully enrolled study on top of standard of care that is being conducted by our partner, Hengrui, and from which we expect data next year. Today, we will introduce TRUEHEART-HCM, which plans a fixed-dose design in which we believe could be an important opportunity to expand the reach and simplicity of BHB-1893. We have received supportive regulatory feedback on this approach and plan to initiate the study in the first half of 2027. In non-obstructive HCM, we are in the midst of initiating NOBLEHEART, which is a placebo-controlled study of BHB-1893. Today's focus is on the newly presented clinical and mechanistic data and how they inform our clinical development plan. We believe that our differentiated pharmacology could result in best-in-disease potential across both obstructive and non-obstructive HCM, which we plan to confirm across the studies outlined in the prior slide.

Travis MurdochCEO and Board Director

We believe this is supported by the robust data presented today, now with one-year follow-up in obstructive HCM, in addition to the nHCM data shared prior this year. We believe that in totality, the pharmacologic and clinical profile of BHB-1893 provides an opportunity to drive differentiated efficacy and safety while providing a highly simplified dosing regimen that could expand access to patients with HCM. I'd now like to pass it over to Dr. Mariko Harper, who will provide an overview of HCM and the current treatment landscape.

Mariko HarperMedical Director of Hypertrophic Cardiomyopathy Center of Excellence

Dr. Harper. Thank you, Dr. Murdoch.

Mariko HarperMedical Director of Hypertrophic Cardiomyopathy Center of Excellence

HCM, or hypertrophic cardiomyopathy, is the most common inherited cardiac disease worldwide, and it continues to have a significant unmet need. HCM is defined by asymmetric left ventricular hypertrophy with an end-diastolic wall thickness of greater than or equal to 15 millimeters or greater than or equal to 13 millimeters in adults with a family history of hypertrophic cardiomyopathy or a positive genetic test. This is in the absence of another identifiable cause of LVH that explains the full magnitude, although concurrent conditions such as hypertension and aortic stenosis are common. HCM is classified into obstructive and non-obstructive HCM based on the presence or absence of left ventricular outflow tract obstruction.

Mariko HarperMedical Director of Hypertrophic Cardiomyopathy Center of Excellence

As you can see, on the left is your healthy heart, and the big difference between the oHCM and the nHCM is the presence of a left ventricular outflow tract obstruction that can be at rest or dynamic, and the magnitude is greater than or equal to 30 millimeters of mercury. But regardless of obstruction, there is a commonality of thickening, a small LV chamber, a hyperdynamic ejection fraction. HCM is a serious and lifelong progressive cardiovascular disease, with the underlying disease burden made up of diastolic dysfunction with impaired myocardial relaxation, elevated LV stiffness, and frequently increased LV filling pressures. There can be ongoing cardiac damage due to chronic myocardial stress, and this often results in an elevated biomarker such as troponin. The long-term myocardial injury and myocardial ischemia can lead to fibrosis and scarring in a majority of patients.

Mariko HarperMedical Director of Hypertrophic Cardiomyopathy Center of Excellence

The symptoms are often heterogeneous, but can cause significant patient limitations, including shortness of breath, chest tightness or chest pain, and fatigue, all of which are worse with exertion. There can be the presence of near-syncope and syncope, both with activity or sometimes even at rest due to arrhythmic potential. The risks with hypertrophic cardiomyopathy over a lifetime include an increased burden of atrial fibrillation, the development of symptomatic heart failure, including a small subset of patients that go on to end-stage disease requiring heart transplantation, the presence of stroke, especially when there is atrial fibrillation, as well as a small subset of patients that suffer sudden cardiac death. In the U.S., we are looking at almost 1 million patients who may be affected with hypertrophic cardiomyopathy, many who may not know that they are at risk of developing this condition.

Mariko HarperMedical Director of Hypertrophic Cardiomyopathy Center of Excellence

The point prevalence is somewhere between about one in 200 to one in 500 patients. Once a patient develops obstructive hypertrophic cardiomyopathy, there is a significant burden on health systems and patients' quality of life, with over one in three being hospitalized annually for all cause, and that oHCM can often increase the risk of the comorbid condition and the reason for hospitalization. Ultimately, this is a lifelong chronic condition that requires management and ongoing therapy. Cardiac myosin inhibitors target the root cause of disease in obstructive hypertrophic cardiomyopathy. For the AHA/ACC 2024 guidelines, first-line therapies are still recommended, and these include beta blockers, non-dihydropyridine calcium channel blockers, and these are really targeting the symptoms, but there is limited HCM trial evidence for effect and long-term benefit and disease modification.

Mariko HarperMedical Director of Hypertrophic Cardiomyopathy Center of Excellence

Septal reduction therapy is also recommended in a subset of patients who have severe limiting symptoms and severe gradients who have failed first-line therapy, but they require an experienced center with experienced high-volume surgical expertise. Cardiac myosin inhibitors were introduced and recommended in the guidelines in 2024, and they really do target the underlying pathophysiology of obstructive HCM. Cardiac myosin inhibitors treat the HCM at the level of the cardiac sarcomere, and they attenuate that hypercontractility. As you can see, going from an untreated oHCM to a CMI-treated oHCM heart, the septum may remain thick for quite some time, but the LV cavity starts to enlarge, the sleeve of that hypercontractility attenuates closer to normal, the outflow tract obstruction is abolished, and that systolic anterior motion of that mitral valve is realigned, and this can significantly improve mitral regurgitation.

Mariko HarperMedical Director of Hypertrophic Cardiomyopathy Center of Excellence

We also know that over time, this can normalize or improve left atrial size. CMIs directly target the HCM pathophysiology by reducing the number of force-generating cross-bridge formation closer to normal. HCM is a disease of the cardiac sarcomere, and cardiac myosin inhibitors attenuate that hypercontractility, which is the hallmark of HCM, closer to a normal magnitude of cross-bridge cycling. In doing so, it improves the myocardial energetics, the diastolic function, relieves the left ventricular outflow tract obstruction, and the goal is also to make our patients feel and function better. CMIs have improved oHCM care, and I would argue that in my clinical practice, it has been a game-changer over the last several years. But there remains significant unmet needs and a need for greater efficacy and convenience in allowing these CMIs to be more democratically available across the U.S.

Mariko HarperMedical Director of Hypertrophic Cardiomyopathy Center of Excellence

First-generation CMIs have proved the mechanism of modulating cross-bridge formation and attenuating that closer to normal. They're effective in reducing the left ventricular outflow tract gradient by 50%-60%. They do improve feel and function, and we've seen this in multiple clinical trials. They increase peak VO2 on cardiopulmonary exercise testing, and they improve patient-reported outcomes, KCCQ and NYHA. There's an established market with a validated mechanism. However, there is an opportunity for next-generation CMIs. There remains a large percentage of patients who are non-responders or partial responders. There is an LVEF cost that caps the gradient benefit, and the long titration and monitoring is a significant burden for patients, healthcare providers, and health systems. The long half-life, the slow onset and reversal of currently available agents may make them cumbersome to use, to get to target dose, but also to be able to reverse.

Travis MurdochCEO and Board Director

Thank you, Dr. Harper. Let's speak now to the obstructive HCM data presented today at AHA. The study presented today was the open-label extension of the phase II study previously shared at ACC earlier this year. In this study, all 42 patients chose to participate in a 52-week extension, where following a washout, they were re-baselined on cardiopulmonary exercise testing, or CPET, echocardiography, and clinical parameters, and then initiated on 40 mg BID of BHB-1893, with the opportunity to titrate at week one and week two to 60 and 80 mg. Patients had repeat assessments throughout the study, notably by CPET measurements that were repeated at week 52. After the washout from the core treatment period, gradients and clinical parameters were noted to revert to pre-treatment levels. These patients had a high baseline gradient.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day